Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Nanology
- 18 Dec 2017 According to a Nanology media release, first patient has been enrolled.
- 11 Aug 2017 Status changed from not yet recruiting to recruiting.
- 12 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jun 2017.